{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:19:57Z","timestamp":1790651997465,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1007\/s00415-019-09180-9","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T12:26:57Z","timestamp":1547209617000},"page":"642-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study"],"prefix":"10.1007","volume":"266","author":[{"given":"V.","family":"Shaygannejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fayyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Badihian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mirmosayyeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Manouchehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ashtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8551-0947","authenticated-orcid":false,"given":"N.","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"9180_CR1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","volume":"69","author":"S Hinson","year":"2007","unstructured":"Hinson S, Pittock SJ, Lucchinetti CF, Roemer S, Fryer J, Kryzer T, Lennon VA (2007) Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69:2221\u20132231","journal-title":"Neurology"},{"key":"9180_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006574","author":"S-H Kim","year":"2018","unstructured":"Kim S-H, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung H-P, Asgari N (2018) Racial differences in neuromyelitis optica spectrum disorder. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000006574","journal-title":"Neurology"},{"key":"9180_CR3","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1212\/NXI.0000000000000134","volume":"2","author":"E Melamed","year":"2015","unstructured":"Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ (2015) Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2:e134","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"9180_CR4","first-page":"864","volume":"22","author":"IK Sand","year":"2016","unstructured":"Sand IK (2016) Neuromyelitis optica spectrum disorders. Continuum 22:864\u2013896","journal-title":"Continuum"},{"key":"9180_CR5","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE (2002) A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 125:1450\u20131461","journal-title":"Brain"},{"key":"9180_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/1756285616632653","volume":"9","author":"N Collongues","year":"2016","unstructured":"Collongues N, de Seze J (2016) An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord 9:180\u2013188","journal-title":"Ther Adv Neurol Disord"},{"key":"9180_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, Opera I, Investigators OIC (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221\u2013234","journal-title":"N Engl J Med"},{"key":"9180_CR8","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jaci.2010.02.018","volume":"125","author":"AM Vale","year":"2010","unstructured":"Vale AM, Schroeder HW Jr (2010) Clinical consequences of defects in B-cell development. J Allergy Clin Immunol 125:778\u2013787","journal-title":"J Allergy Clin Immunol"},{"key":"9180_CR9","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepa\u0144ski L, Szechi\u0144ski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell\u2014targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"key":"9180_CR10","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.4049\/jimmunol.1700822","volume":"199","author":"Q Wang","year":"2017","unstructured":"Wang Q, Racine JJ, Ratiu JJ, Wang S, Ettinger R, Wasserfall C, Atkinson MA, Serreze DV (2017) Transient BAFF blockade inhibits type 1 diabetes development in nonobese diabetic mice by enriching immunoregulatory B lymphocytes sensitive to deletion by anti-CD20 cotherapy. J Immunol 199:3757\u20133770","journal-title":"J Immunol"},{"key":"9180_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/1735-1995.200275","volume":"22","author":"M Etemadifar","year":"2017","unstructured":"Etemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, Askari M, Fayyazi E (2017) Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci 22:18","journal-title":"J Res Med Sci"},{"key":"9180_CR12","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles T-M, Dallaire BK (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"9180_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMOD (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"issue":"7","key":"9180_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/archneur.65.7.913","volume":"65","author":"P Waters","year":"2008","unstructured":"Waters P, Jarius S, Littleton E, Leite MI, Jacob S, Gray B, Geraldes R, Vale T, Jacob A, Palace J, Maxwell S (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65(7):913\u2013919","journal-title":"Arch Neurol"},{"key":"9180_CR15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","volume":"263","author":"P Annovazzi","year":"2016","unstructured":"Annovazzi P, Capobianco M, Moiola L, Patti F, Frau J, Uccelli A, Centonze D, Perini P, Tortorella C, Prosperini L, Lus G, Fuiani A, Falcini M, Martinelli V, Comi G, Ghezzi A (2016) Rituximab in the treatment of neuromyelitis optica: a multicentre Italian observational study. J Neurol 263:1727\u20131735","journal-title":"J Neurol"},{"key":"9180_CR16","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76:1310\u20131315","journal-title":"Neurology"},{"key":"9180_CR17","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R (2016) Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73:1342\u20131348","journal-title":"JAMA Neurol"},{"key":"9180_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.nrl.2014.09.001","volume":"30","author":"MJ Fernandez-Megia","year":"2015","unstructured":"Fernandez-Megia MJ, Casanova-Estruch B, Perez-Miralles F, Ruiz-Ramos J, Alcala-Vicente C, Poveda-Andres JL (2015) Clinical evaluation of rituximab treatment for neuromyelitis optica. Neurologia 30:461\u2013464","journal-title":"Neurologia"},{"key":"9180_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jns.2012.09.024","volume":"324","author":"VH Ip","year":"2013","unstructured":"Ip VH, Lau AY, Au LW, Fan FS, Chan AY, Mok VC, Wong KS (2013) Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci 324:38\u201339","journal-title":"J Neurol Sci"},{"key":"9180_CR20","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2\u00a0years. Arch Neurol 68:1412\u20131420","journal-title":"Arch Neurol"},{"key":"9180_CR21","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70:1110\u20131117","journal-title":"JAMA Neurol"},{"key":"9180_CR22","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/1352458511404586","volume":"17","author":"GS Bedi","year":"2011","unstructured":"Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17:1225\u20131230","journal-title":"Mult Scler"},{"key":"9180_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1352458515594042","volume":"22","author":"M Radaelli","year":"2016","unstructured":"Radaelli M, Moiola L, Sangalli F, Esposito F, Barcella V, Ferre L, Rodegher M, Colombo B, Fazio R, Martinelli V, Comi G (2016) Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler 22:511\u2013519","journal-title":"Mult Scler"},{"key":"9180_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1756285609356135","volume":"3","author":"ML Kosmidis","year":"2010","unstructured":"Kosmidis ML, Dalakas MC (2010) Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 3:93\u2013105","journal-title":"Ther Adv Neurol Disord"},{"key":"9180_CR25","doi-asserted-by":"publisher","first-page":"e0190425","DOI":"10.1371\/journal.pone.0190425","volume":"13","author":"AB Memon","year":"2018","unstructured":"Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, Chorostecki J, Tselis A, Seraji-Bozorgzad N, Khan O (2018) Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One 13:e0190425","journal-title":"PLoS One"},{"key":"9180_CR26","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1086\/380097","volume":"188","author":"A Kantele","year":"2003","unstructured":"Kantele A, Mottonen T, Ala-Kaila K, Arvilommi HS (2003) P Fimbria-specific B cell responses in patients with urinary tract infection. J Infect Dis 188:1885\u20131891","journal-title":"J Infect Dis"},{"key":"9180_CR27","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","volume":"5","author":"A Marcinn\u00f2","year":"2018","unstructured":"Marcinn\u00f2 A, Marnetto F, Valentino P, Martire S, Balbo A, Drago A, Leto M, Capobianco M, Panzica G, Bertolotto A (2018) Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 5:e498","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"9180_CR28","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, Perry A, Yerra R, Schmidt R, Alvarez E, Tyler KL (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68:1156\u20131164","journal-title":"Arch Neurol"},{"key":"9180_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jiph.2014.11.006","volume":"8","author":"JA Al-Tawfiq","year":"2015","unstructured":"Al-Tawfiq JA, Banda RW, Daabil RA, Dawamneh MF (2015) Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: a case report and literature review. J Infect Public Health 8:493\u2013497","journal-title":"J Infect Public Health"},{"key":"9180_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.autrev.2008.07.006","volume":"8","author":"ES Molloy","year":"2008","unstructured":"Molloy ES, Calabrese LH (2008) Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 8:144\u2013146","journal-title":"Autoimmun Rev"},{"key":"9180_CR31","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72:1496\u20131502","journal-title":"Ann Rheum Dis"},{"key":"9180_CR32","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71:324\u2013330","journal-title":"JAMA Neurol"},{"key":"9180_CR33","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F (2017) Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 264:2003\u20132009","journal-title":"J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-019-09180-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09180-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09180-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:43:06Z","timestamp":1659055386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-019-09180-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"alternative-id":["9180"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09180-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,11]]},"assertion":[{"value":"7 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by research ethics committee of Isfahan University of Medical Sciences (Approval Code: IR.MUI.RSEARCH.REC.1397.171) and it was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}},{"value":"Written informed consents were obtained from all patients upon enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}